Renaissance Technologies - ARBUTUS BIOPHARMA CORP ownership

ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 123 filers reported holding ARBUTUS BIOPHARMA CORP in Q3 2022. The put-call ratio across all filers is 1.01 and the average weighting 0.1%.

Quarter-by-quarter ownership
Renaissance Technologies ownership history of ARBUTUS BIOPHARMA CORP
ValueSharesWeighting
Q2 2023$739
-11.3%
321,128
+16.8%
0.00%0.0%
Q1 2023$833
+915.9%
274,991
+682.6%
0.00%
Q4 2022$82
-99.9%
35,136
-23.0%
0.00%
Q3 2022$87,000
-97.4%
45,660
-95.5%
0.00%
-100.0%
Q1 2021$3,345,000
+115.1%
1,004,500
+129.4%
0.00%
+100.0%
Q4 2020$1,555,000
+1300.9%
437,963
+615.5%
0.00%
Q2 2020$111,000
-56.8%
61,207
-63.6%
0.00%
Q3 2019$257,000
-30.7%
168,312
-5.5%
0.00%
Q2 2019$371,000
-19.5%
178,200
+265.4%
0.00%
Q3 2018$461,000
-84.9%
48,766
-90.1%
0.00%
-100.0%
Q2 2018$3,048,000
+150.2%
494,152
+102.9%
0.00%
+100.0%
Q1 2018$1,218,000
-40.1%
243,500
-39.5%
0.00%
-50.0%
Q4 2017$2,033,000
+104.1%
402,573
+150.7%
0.00%
+100.0%
Q3 2017$996,000
+31.6%
160,610
-23.6%
0.00%0.0%
Q2 2017$757,000
+86.9%
210,239
+68.8%
0.00%0.0%
Q1 2017$405,000
+1091.2%
124,573
+785.1%
0.00%
Q4 2016$34,000
-91.5%
14,074
-87.9%
0.00%
-100.0%
Q3 2016$399,000
+46.7%
116,100
+48.4%
0.00%0.0%
Q2 2016$272,000
-76.2%
78,215
-71.7%
0.00%
-50.0%
Q1 2016$1,143,000
-27.8%
276,800
-22.2%
0.00%
-33.3%
Q4 2015$1,584,000
+136.1%
356,000
+223.3%
0.00%
+50.0%
Q3 2015$671,000110,1000.00%
Other shareholders
ARBUTUS BIOPHARMA CORP shareholders Q3 2022
NameSharesValueWeighting ↓
JACOB ASSET MANAGEMENT OF NEW YORK LLC 340,000$1,459,0000.53%
RTW INVESTMENTS, LP 4,733,323$20,306,0000.31%
APIS CAPITAL ADVISORS, LLC 70,000$300,0000.29%
Hudson Bay Capital Management LP 1,800,000$7,722,0000.10%
COWEN AND COMPANY, LLC 249,215$1,069,0000.05%
Kerrisdale Advisers, LLC 100,000$429,0000.05%
Woodline Partners LP 496,172$2,129,0000.04%
Shay Capital LLC 60,000$257,0000.03%
Walleye Capital LLC 231,037$991,0000.03%
BOOTHBAY FUND MANAGEMENT, LLC 212,700$912,0000.02%
View complete list of ARBUTUS BIOPHARMA CORP shareholders